Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Zastaprazan with Amoxicillin and Clarithromycin in Healthy Volunteers
NCT05194046Phase 1Completed
- Sponsor
- Onconic Therapeutics Inc.
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zastaprazan in Helicobacter pylori infection (6 arms), sponsored by Onconic Therapeutics Inc. Primary endpoints: Maximum Plasma Concentration at Steady State at Day 5 and Area Under the Curve Over the Dosing Interval at Day 5. Started Nov 2020; status: completed.
02
Drugs
zastaprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05194046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194046.